The company developed an antigen protein for the development of reagents for diagnosis of COVID-19 IgM/IgG, and began the development of GBT COVID-19 IgM/IgG Rapid Kit, which can be examined within 10 to 15 minutes. The KFDA approval will be available by September, according to the development manager.
글로리바이오텍은 COVID-19 IgM/IgG 진단용 시약 개발을 위한 항원 단백질을 개발하고,
10~15분 내 검사가 가능한 GBT COVID-19 IgM/IgG Rapid Kit 개발에 착수했다.
개발 책임자에 따르면 식품의약품안전청 승인은 9월까지 가능할 것이라고 한다.
The company developed an antigen protein for the development of reagents for diagnosis of COVID-19 IgM/IgG, and began the development of GBT COVID-19 IgM/IgG Rapid Kit, which can be examined within 10 to 15 minutes. The KFDA approval will be available by September, according to the development manager.
글로리바이오텍은 COVID-19 IgM/IgG 진단용 시약 개발을 위한 항원 단백질을 개발하고,
10~15분 내 검사가 가능한 GBT COVID-19 IgM/IgG Rapid Kit 개발에 착수했다.
개발 책임자에 따르면 식품의약품안전청 승인은 9월까지 가능할 것이라고 한다.